OSLO, Norway, March 24, 2020 /PRNewswire/ -- The Board of
Directors of Nordic Nanovector ASA ("Nordic Nanovector" or the
"Company") has on 24 March 2020
decided to grant 561,500 Performance Share Units ("PSUs") to
employees in accordance with the authorisation granted at the
Annual General Meeting held on 25 April
2019 (the "AGM").
The terms and conditions of the PSUs, which are part of the
Company's long-term incentive plan for employees, are described on
pages 18-25 in the Company's annual report for 2018.
The PSUs are granted without consideration. The PSUs are
non-transferable and will vest three years after the date of grant
subject to satisfaction of the applicable vesting conditions. Each
vested PSUs will give the holder the right to acquire one share in
the Company at an exercise price corresponding to the par value of
the shares being NOK 0.20.
In accordance with the resolution at the AGM, the PSUs are
secured by a corresponding number of free-standing warrants. The
sole purpose of the warrants is to ensure delivery of shares in the
Company upon exercise of the PSUs. The warrants do not give the PSU
holders (or the option holders) a right to subscribe for any
additional shares in the Company.
Of the 561,500 allocated PSUs, 350,000 PSUs have been granted to
members of the Company's executive management, 17,000 PSUs have
been granted to new employees and 194,500 PSUs have been granted to
other current employees.
The following primary insiders were granted PSUs on 24 March 2019:
Lars Nieba, interim CEO was granted 60,000 PSUs. Lars Nieba now
holds 110,000 PSUs and 0 shares
Tone Kvåle, CFO was granted 45,000 PSUs. Tone Kvåle now holds
90,000 PSUs, 315,000 options and 191,275 shares including shares to
related party
Jostein Dahle, CSO was granted
45,000 PSUs. Jostein Dahle now holds
77,000 PSUs, 150,000 options and 204,958 shares including shares to
related party
Marco Renoldi, COO was granted 45,000 PSUs. Marco Renoldi now
holds 95,000 PSUs, 464,137 options and 74,000 shares
Rita Dege, CHRO was granted
45,000 PSUs. Rita Dege now holds
71,500 PSUs, 67,000 options and 4,754 shares
Malene Brondberg, VP IR and CC was granted 45,000 PSUs. Malene
Brondberg now holds 85,000 PSUs, 0 options and 9,455 shares
Rosemarie Corrigan, CQO was
granted 45,000 PSUs. Rosemarie
Corrigan now holds 85,000 PSUs, 0 options and 2,436
shares
Gabriele Elbl, VP Global
Regulatory Affairs was granted 20,000 PSUs. Gabriele Elbl now holds 50,000 PSUs, 0 options
and 0 shares
The PSUs allocated to the management of the Company is in
accordance with the Board of Director's declaration on salaries and
other remuneration to the senior executive management, as approved
by the Company's AGM.
The total number of outstanding options and PSUs are now
1,718,410 and 425,250 respectively. Subject to all vesting
conditions being fulfilled exercise of the options and PSUs would
create a 3,93% dilution of the outstanding shares on a fully
diluted basis.
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication
with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets.
Further information can be found at
www.nordicnanovector.com.
This information is subject to a duty of disclosure pursuant to
Sections 4-2 and 5-12 of the Securities Trading Act.
For further information, please contact:
Jan H.
Egberts
chairman
Cell: +31-6-1467 2518
Email: janegberts@aol.com
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector-asa---allocation-of-psus,c3067035